Literature DB >> 18500464

Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease.

Madhan Masilamani1, Narendiran Rajasekaran, Anjana Singh, Hui-Zhi Low, Kerstin Albus, Swantje Anders, Frank Behne, Peter Eiermann, Katharina König, Clarissa Mindnich, Teodora Ribarska, Harald Illges.   

Abstract

Complement receptor type II/CD21 is the functional receptor for complement fragments such as C3d, iC3b and the Epstein Barr Virus. A soluble form of CD21 (sCD21) is shed from lymphocytes surface and is able to bind to its ligands found in the plasma. The amount of sCD21 in serum may modulate immunity as the plasma levels are correlated with autoimmune conditions, such as Systemic Lupus Erythematosus, Rheumatoid Arthritis and Sjoegren's Syndrome. Because of the fact that pregnancy may lead to remission of autoimmune diseases we determined the serum levels of sCD21 during pregnancy and postpartum. The serum sCD21 levels during pregnancy are significantly lower as compared to that of the healthy controls. There were no significant differences in sCD21 levels between the mother and the cord blood also immediately after parturition. Restoration of sCD21 levels to normal values takes between 6 weeks and 1 year after childbirth. Our study indicates that CD21-shedding is affected during pregnancy comparable to that of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500464     DOI: 10.1007/s00296-008-0604-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

Review 1.  Functional properties of soluble CD21.

Authors:  V Frémeaux-Bacchi; J P Kolb; S Rakotobé; M D Kazatchkine; E M Fischer
Journal:  Immunopharmacology       Date:  1999-05

2.  CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.

Authors:  R H Carter; D T Fearon
Journal:  Science       Date:  1992-04-03       Impact factor: 47.728

3.  Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response.

Authors:  W Timens; A Boes; T Rozeboom-Uiterwijk; S Poppema
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

4.  Expression of the C3d/EBV receptor and of other cell membrane surface markers is altered upon HIV-1 infection of myeloid, T, and B cells.

Authors:  C Larcher; T F Schulz; J Hofbauer; P Hengster; N Romani; H Wachter; M P Dierich
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

Review 5.  Infant B cell responses to polysaccharide determinants.

Authors:  G T Rijkers; E A Sanders; M A Breukels; B J Zegers
Journal:  Vaccine       Date:  1998 Aug-Sep       Impact factor: 3.641

6.  Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis.

Authors:  M Masilamani; J von Kempis; H Illges
Journal:  Rheumatology (Oxford)       Date:  2003-07-16       Impact factor: 7.580

7.  B cell activation leads to shedding of complement receptor type II (CR2/CD21).

Authors:  Madhan Masilamani; Daniela Kassahn; Stefan Mikkat; Michael O Glocker; Harald Illges
Journal:  Eur J Immunol       Date:  2003-09       Impact factor: 5.532

8.  Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes.

Authors:  A W Griffioen; S W Franklin; B J Zegers; G T Rijkers
Journal:  Clin Immunol Immunopathol       Date:  1993-10

9.  A critical role for complement in maintenance of self-tolerance.

Authors:  A P Prodeus; S Goerg; L M Shen; O O Pozdnyakova; L Chu; E M Alicot; C C Goodnow; M C Carroll
Journal:  Immunity       Date:  1998-11       Impact factor: 31.745

10.  Immunologic and inflammatory responses during pregnancy.

Authors:  D Holland; P Bretscher; A S Russell
Journal:  J Clin Lab Immunol       Date:  1984-08
View more
  1 in total

1.  Serum levels of soluble CD21 in patients with systemic sclerosis.

Authors:  Manabu Tomita; Takafumi Kadono; Norihito Yazawa; Tomohiko Kawashima; Zenshiro Tamaki; Ryuichi Ashida; Hanako Ohmatsu; Yoshihide Asano; Makoto Sugaya; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.